What is Microcyn® Technology
The Microcyn Technology platform has demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores.
Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the shelf-stable Microcyn¨ Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform enables the creation of a biocompatible solution containing active oxychlorine compounds. Solutions derived from the shelf-stable Microcyn Technology platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. Unlike other products it does not harm healthy tissue and thus speeds healing. The technology (click to watch a video) has also demonstrated wound healing in chronic and acute wounds in clinical investigational studies. Microcyn Technology is also used in the animal care product called Vetericyn.
Innovacyn, Inc. is a privately held American company formed to provide premier healthcare products. Innovacyn embraces scientific research to deliver innovative products and world-class operations to its stakeholders. The company currently markets advanced healthcare products based on the Microcyn® Technology platform to both the human and animal markets. Innovacyn promotes only those products it believes will truly revolutionize healthcare - products that create value for its trade partners and enrich lives for consumers.
Innovacyn wants to be the company of choice for:
- Our team members and their families
- Our customers and their customers
- Our suppliers